Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy

Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic bl...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Shashni, Babita [verfasserIn] Nagasaki, Yukio [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle

Übergeordnetes Werk:	Enthalten in: Nano today - Amsterdam [u.a.] : Elsevier, 2006, 54
Übergeordnetes Werk:	volume:54

DOI / URN:	10.1016/j.nantod.2023.102103

Katalog-ID:	ELV066913985

Internformat


LEADER	01000caa a22002652 4500
001	ELV066913985
003	DE-627
005	20240209093017.0
007	cr uuu---uuuuu
008	240207s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.nantod.2023.102103 \|2 doi
035			\|a (DE-627)ELV066913985
035			\|a (ELSEVIER)S1748-0132(23)00352-3
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
082	0	4	\|a 540 \|a 660 \|q VZ
084			\|a 35.18 \|2 bkl
084			\|a 51.45 \|2 bkl
084			\|a 50.94 \|2 bkl
084			\|a 33.68 \|2 bkl
100	1		\|a Shashni, Babita \|e verfasserin \|4 aut
245	1	0	\|a Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy
264		1	\|c 2023
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications.
650		4	\|a Butyric acid
650		4	\|a Short-chain fatty acids
650		4	\|a Radiosensitizer
650		4	\|a Self-assembling polymer micelle
650		4	\|a Polymeric prodrug
650		4	\|a Nanoparticle
700	1		\|a Nagasaki, Yukio \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Nano today \|d Amsterdam [u.a.] : Elsevier, 2006 \|g 54 \|h Online-Ressource \|w (DE-627)508725259 \|w (DE-600)2224882-1 \|w (DE-576)258762047 \|x 1878-044X \|7 nnns
773	1	8	\|g volume:54
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 35.18 \|j Kolloidchemie \|j Grenzflächenchemie \|q VZ
936	b	k	\|a 51.45 \|j Werkstoffe mit besonderen Eigenschaften \|q VZ
936	b	k	\|a 50.94 \|j Mikrosystemtechnik \|j Nanotechnologie \|q VZ
936	b	k	\|a 33.68 \|j Oberflächen \|j Dünne Schichten \|j Grenzflächen \|x Physik \|q VZ
951			\|a AR
952			\|d 54

Indexfelder

author_variant	b s bs y n yn
matchkey_str	article:1878044X:2023----::efsebiguyiaiporgcsssniief
hierarchy_sort_str	2023
bklnumber	35.18 51.45 50.94 33.68
publishDate	2023
allfields	10.1016/j.nantod.2023.102103 doi (DE-627)ELV066913985 (ELSEVIER)S1748-0132(23)00352-3 DE-627 ger DE-627 rda eng 540 660 VZ 35.18 bkl 51.45 bkl 50.94 bkl 33.68 bkl Shashni, Babita verfasserin aut Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications. Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle Nagasaki, Yukio verfasserin aut Enthalten in Nano today Amsterdam [u.a.] : Elsevier, 2006 54 Online-Ressource (DE-627)508725259 (DE-600)2224882-1 (DE-576)258762047 1878-044X nnns volume:54 GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.18 Kolloidchemie Grenzflächenchemie VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ 50.94 Mikrosystemtechnik Nanotechnologie VZ 33.68 Oberflächen Dünne Schichten Grenzflächen Physik VZ AR 54
spelling	10.1016/j.nantod.2023.102103 doi (DE-627)ELV066913985 (ELSEVIER)S1748-0132(23)00352-3 DE-627 ger DE-627 rda eng 540 660 VZ 35.18 bkl 51.45 bkl 50.94 bkl 33.68 bkl Shashni, Babita verfasserin aut Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications. Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle Nagasaki, Yukio verfasserin aut Enthalten in Nano today Amsterdam [u.a.] : Elsevier, 2006 54 Online-Ressource (DE-627)508725259 (DE-600)2224882-1 (DE-576)258762047 1878-044X nnns volume:54 GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.18 Kolloidchemie Grenzflächenchemie VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ 50.94 Mikrosystemtechnik Nanotechnologie VZ 33.68 Oberflächen Dünne Schichten Grenzflächen Physik VZ AR 54
allfields_unstemmed	10.1016/j.nantod.2023.102103 doi (DE-627)ELV066913985 (ELSEVIER)S1748-0132(23)00352-3 DE-627 ger DE-627 rda eng 540 660 VZ 35.18 bkl 51.45 bkl 50.94 bkl 33.68 bkl Shashni, Babita verfasserin aut Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications. Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle Nagasaki, Yukio verfasserin aut Enthalten in Nano today Amsterdam [u.a.] : Elsevier, 2006 54 Online-Ressource (DE-627)508725259 (DE-600)2224882-1 (DE-576)258762047 1878-044X nnns volume:54 GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.18 Kolloidchemie Grenzflächenchemie VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ 50.94 Mikrosystemtechnik Nanotechnologie VZ 33.68 Oberflächen Dünne Schichten Grenzflächen Physik VZ AR 54
allfieldsGer	10.1016/j.nantod.2023.102103 doi (DE-627)ELV066913985 (ELSEVIER)S1748-0132(23)00352-3 DE-627 ger DE-627 rda eng 540 660 VZ 35.18 bkl 51.45 bkl 50.94 bkl 33.68 bkl Shashni, Babita verfasserin aut Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications. Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle Nagasaki, Yukio verfasserin aut Enthalten in Nano today Amsterdam [u.a.] : Elsevier, 2006 54 Online-Ressource (DE-627)508725259 (DE-600)2224882-1 (DE-576)258762047 1878-044X nnns volume:54 GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.18 Kolloidchemie Grenzflächenchemie VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ 50.94 Mikrosystemtechnik Nanotechnologie VZ 33.68 Oberflächen Dünne Schichten Grenzflächen Physik VZ AR 54
allfieldsSound	10.1016/j.nantod.2023.102103 doi (DE-627)ELV066913985 (ELSEVIER)S1748-0132(23)00352-3 DE-627 ger DE-627 rda eng 540 660 VZ 35.18 bkl 51.45 bkl 50.94 bkl 33.68 bkl Shashni, Babita verfasserin aut Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications. Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle Nagasaki, Yukio verfasserin aut Enthalten in Nano today Amsterdam [u.a.] : Elsevier, 2006 54 Online-Ressource (DE-627)508725259 (DE-600)2224882-1 (DE-576)258762047 1878-044X nnns volume:54 GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.18 Kolloidchemie Grenzflächenchemie VZ 51.45 Werkstoffe mit besonderen Eigenschaften VZ 50.94 Mikrosystemtechnik Nanotechnologie VZ 33.68 Oberflächen Dünne Schichten Grenzflächen Physik VZ AR 54
language	English
source	Enthalten in Nano today 54 volume:54
sourceStr	Enthalten in Nano today 54 volume:54
format_phy_str_mv	Article
bklname	Kolloidchemie Grenzflächenchemie Werkstoffe mit besonderen Eigenschaften Mikrosystemtechnik Nanotechnologie Oberflächen Dünne Schichten Grenzflächen
institution	findex.gbv.de
topic_facet	Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle
dewey-raw	540
isfreeaccess_bool	false
container_title	Nano today
authorswithroles_txt_mv	Shashni, Babita @@aut@@ Nagasaki, Yukio @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	508725259
dewey-sort	3540
id	ELV066913985
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV066913985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240209093017.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240207s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nantod.2023.102103</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV066913985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1748-0132(23)00352-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.18</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.94</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shashni, Babita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Butyric acid</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Short-chain fatty acids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiosensitizer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Self-assembling polymer micelle</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymeric prodrug</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanoparticle</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagasaki, Yukio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Nano today</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier, 2006</subfield><subfield code="g">54</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)508725259</subfield><subfield code="w">(DE-600)2224882-1</subfield><subfield code="w">(DE-576)258762047</subfield><subfield code="x">1878-044X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.18</subfield><subfield code="j">Kolloidchemie</subfield><subfield code="j">Grenzflächenchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.45</subfield><subfield code="j">Werkstoffe mit besonderen Eigenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.94</subfield><subfield code="j">Mikrosystemtechnik</subfield><subfield code="j">Nanotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.68</subfield><subfield code="j">Oberflächen</subfield><subfield code="j">Dünne Schichten</subfield><subfield code="j">Grenzflächen</subfield><subfield code="x">Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield></datafield></record></collection>
author	Shashni, Babita
spellingShingle	Shashni, Babita ddc 540 bkl 35.18 bkl 51.45 bkl 50.94 bkl 33.68 misc Butyric acid misc Short-chain fatty acids misc Radiosensitizer misc Self-assembling polymer micelle misc Polymeric prodrug misc Nanoparticle Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy
authorStr	Shashni, Babita
ppnlink_with_tag_str_mv	@@773@@(DE-627)508725259
format	electronic Article
dewey-ones	540 - Chemistry & allied sciences 660 - Chemical engineering
delete_txt_mv	keep
author_role	aut aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
issn	1878-044X
topic_title	540 660 VZ 35.18 bkl 51.45 bkl 50.94 bkl 33.68 bkl Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy Butyric acid Short-chain fatty acids Radiosensitizer Self-assembling polymer micelle Polymeric prodrug Nanoparticle
topic	ddc 540 bkl 35.18 bkl 51.45 bkl 50.94 bkl 33.68 misc Butyric acid misc Short-chain fatty acids misc Radiosensitizer misc Self-assembling polymer micelle misc Polymeric prodrug misc Nanoparticle
topic_unstemmed	ddc 540 bkl 35.18 bkl 51.45 bkl 50.94 bkl 33.68 misc Butyric acid misc Short-chain fatty acids misc Radiosensitizer misc Self-assembling polymer micelle misc Polymeric prodrug misc Nanoparticle
topic_browse	ddc 540 bkl 35.18 bkl 51.45 bkl 50.94 bkl 33.68 misc Butyric acid misc Short-chain fatty acids misc Radiosensitizer misc Self-assembling polymer micelle misc Polymeric prodrug misc Nanoparticle
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Nano today
hierarchy_parent_id	508725259
dewey-tens	540 - Chemistry 660 - Chemical engineering
hierarchy_top_title	Nano today
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)508725259 (DE-600)2224882-1 (DE-576)258762047
title	Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy
ctrlnum	(DE-627)ELV066913985 (ELSEVIER)S1748-0132(23)00352-3
title_full	Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy
author_sort	Shashni, Babita
journal	Nano today
journalStr	Nano today
lang_code	eng
isOA_bool	false
dewey-hundreds	500 - Science 600 - Technology
recordtype	marc
publishDateSort	2023
contenttype_str_mv	zzz
author_browse	Shashni, Babita Nagasaki, Yukio
container_volume	54
class	540 660 VZ 35.18 bkl 51.45 bkl 50.94 bkl 33.68 bkl
format_se	Elektronische Aufsätze
author-letter	Shashni, Babita
doi_str_mv	10.1016/j.nantod.2023.102103
dewey-full	540 660
author2-role	verfasserin
title_sort	self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy
title_auth	Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy
abstract	Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications.
abstractGer	Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications.
abstract_unstemmed	Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700
title_short	Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy
remote_bool	true
author2	Nagasaki, Yukio
author2Str	Nagasaki, Yukio
ppnlink	508725259
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1016/j.nantod.2023.102103
up_date	2024-07-06T19:26:22.420Z
_version_	1803858982911082496
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV066913985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240209093017.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240207s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nantod.2023.102103</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV066913985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1748-0132(23)00352-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.18</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.94</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shashni, Babita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Butyric acid, is reported to radiosensitize cancer cell lines in vitro. Their short systemic half-lives may explain their lack of in vivo efficacy. To manage the unsuitable pharmacokinetics of low-molecular-weight (LMW) butyric acid, we have designed a new polymeric prodrug comprising amphiphilic block copolymers, [poly(ethylene glycol)-b-poly(vinyl butyrate)s] (PEG-b-PV(BA)), with tens of butyric acid units conjugated through enzymatically metabolizable ester linkages as side chains in the hydrophobic segment. PEG-b-PV(BA) spontaneously forms self-assembling nanoparticles (NanoBA) with diameters of tens of nanometers. Pharmacological studies of intraperitoneal administration revealed that the retention of NanoBA in the plasma and tumors was extended up to 48–72 h compared to its LMW counterparts, as evidenced using in vivo imaging, immunoblotting of the PEG segment of the block copolymers, and radioisotope techniques. These results corroborated the LC-MS/MS-based study, validating the prominent in vivo liberation of butyric acid for a prolonged period (24 h) in NanoBA administered group compared to the LMW butyric acid, which cleared within approximately 0.5 h post-administration. Furthermore, radiation treatment after 24 h of intraperitoneal NanoBA administration toward tumor (B16-F10)-bearing mice exhibited significantly slower tumor growth in comparison with control irradiated tumors and LMW butyric acid-treated group, which was attributable to attenuated radioresistance Cox-2 and NF-κβ survival pathways. Current findings demonstrate that our self-assembling nanoparticle NanoBA prodrug substantially enhances the radiosensitizing effect of butyric acid in solid tumors in vivo, supporting the use of NanoBA for future clinical ramifications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Butyric acid</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Short-chain fatty acids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiosensitizer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Self-assembling polymer micelle</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polymeric prodrug</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanoparticle</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagasaki, Yukio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Nano today</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier, 2006</subfield><subfield code="g">54</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)508725259</subfield><subfield code="w">(DE-600)2224882-1</subfield><subfield code="w">(DE-576)258762047</subfield><subfield code="x">1878-044X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.18</subfield><subfield code="j">Kolloidchemie</subfield><subfield code="j">Grenzflächenchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.45</subfield><subfield code="j">Werkstoffe mit besonderen Eigenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.94</subfield><subfield code="j">Mikrosystemtechnik</subfield><subfield code="j">Nanotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.68</subfield><subfield code="j">Oberflächen</subfield><subfield code="j">Dünne Schichten</subfield><subfield code="j">Grenzflächen</subfield><subfield code="x">Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield></datafield></record></collection>
score	7.4000416

Nicht das Richtige dabei?

Schreiben Sie uns!

Self-assembling butyric acid prodrug acts as a sensitizer for cancer radiotherapy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?